Back to Peptide Index

Follistatin

MuscleEvidence Level: researchNot FDA-approved for therapeutic use; ongoing research
Peptide #32

Follistatin is a naturally occurring glycoprotein primarily known for its role in regulating muscle growth by inhibiting myostatin. It has profound effects on muscle development, inflammation, and overall metabolic regulation. It is being researched for its potential in treating muscle-wasting diseases, improving athletic performance, and combating metabolic disorders.

Overview

Follistatin is a glycoprotein involved in muscle growth regulation and inflammation management, with potential roles in metabolic health and anti-aging therapies.

How It Works

Follistatin binds to and neutralizes myostatin, promoting muscle growth and regeneration. It also has anti-inflammatory and metabolic regulation effects.

Clinical Effects

Promotes muscle growth, increases strength, enhances muscle regeneration, reduces inflammation, improves insulin sensitivity, and influences metabolic health.

Therapeutic Applications

Muscle-wasting disorders, sports performance, muscle recovery, metabolic health, obesity management

Research Studies

Clinical Trials

Limited clinical research exists, providing initial insights into its safety and efficacy.

Preclinical Studies

Animal studies demonstrate remarkable muscle mass increases and strength gains.

Frequently Asked Questions

Is Follistatin legally available? Yes, for research purposes. Have human trials been conducted? Limited research exists. What are potential side effects? Minimal in preclinical studies. How is it administered? Subcutaneous or intramuscular injections. Can it be combined with other peptides? Interactions remain largely unexplored. Does it permanently increase muscle mass? Enhances muscle mass during administration.

Quick Information

Safety Information

Safety Profile

Comprehensive safety, efficacy, and dosage guidelines remain undetermined; not approved for human use.

Contraindications

Side Effects: Preclinical studies show minimal side effects; thorough long-term safety profiles in humans require further research. Safety Profile: Comprehensive safety, efficacy, and dosage guidelines remain undetermined; not approved for human use.

Side Effects

Preclinical studies show minimal side effects; thorough long-term safety profiles in humans require further research.

Research References

Lee, S.J., & McPherron, A.C. (2001). Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences. Rodino-Klapac, L.R., et al. (2009). Follistatin gene therapy improves muscle strength and function in mouse models of Duchenne muscular dystrophy. Molecular Therapy. Amthor, H., & Hoogaars, W.M. (2012). Interference with myostatin/ActRIIB signaling as a therapeutic strategy for muscle wasting disorders. Current Opinion in Pharmacology.

Additional Resources

View Source